Faecal Incontinence in Prostate Cancer Survivors Treated Whith Radiotherapy
NCT ID: NCT04262609
Last Updated: 2024-02-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
200 participants
OBSERVATIONAL
2019-07-01
2025-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multicenter Study of Hypofractionated Postoperative Radiotherapy in Patients Diagnosed With Prostate Carcinoma
NCT04484038
Prospective Evaluation of Focal Brachytherapy Using Cesium-131 For Patients With Low Risk Prostate Cancer
NCT02290366
Radiation Therapy Followed by Surgery in High-Risk, Localized Carcinoma of the Prostate
NCT00691977
Innovative Planning and Guidance System for Prostate Focal Brachytherapy
NCT03160365
Hypofractionated Radiotherapy for Prostate Cancer
NCT03851926
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The safe dose of irradiation of the anal sphincter with radiotherapy modern techniques (volumetric modulated arc therapy with moderately hypofracctionation) is unknown.
Urgency and faecal incontinence greatly affects the quality of life of these patients.
Therefore, it is interesting to implement strategies to protect the anatomical structures involved in fecal continence.
The objective of the study is to determine the incidence of faecal incontinence in prostate cancer survivors treated with modern moderately hypofractionated radiation therapy and correlate the dose received by the anal sphincter with the degree of faecal incontinence.
The investigators also want to evaluate the quality of life of these patients
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
hypofractionated radiotherapy
volumetric modulated moderately fractionated arc therapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Other active cancer
* Mental disorder
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Consorci Sanitari de Terrassa
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Joan Lozano Galan
Principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joan Lozano, MD
Role: PRINCIPAL_INVESTIGATOR
Consorci Sanitari de Terrassa
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Consorci Sanitari de Terrassa
Terrassa, Catalonia, Spain
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lozano J, Feltes N, Colomer M, Lizondo M, Carmona M, Romero C, Ribas Y, Paredes S, Galdeano M, Sole JM. Fecal incontinence after moderately hypofractionated volumetric modulated arc therapy for prostate cancer: incidence and impact on quality of life. Clin Transl Oncol. 2025 Oct;27(10):4003-4010. doi: 10.1007/s12094-025-03926-w. Epub 2025 Apr 22.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ONCORTCST2020-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.